Alyssa Musso
Senior Scientist, Drug Safety Research and Development
Alyssa Musso received a B.S. in Forensic Science and a B.S. in Chemistry from the University of New Haven in 2013. In 2016, Alyssa received a M.S. in Pharmacology and Toxicology from the University of the Sciences in Philadelphia. Following graduate school, she worked as an analytical chemist at Eurofins Lancaster Laboratories for two years and then joined the Analytical Research and Development team at Pfizer in Groton, Connecticut in 2018. In Analytical Research and Development (ARD), Alyssa worked as a chemist and performed analytical testing of active pharmaceutical ingredients (APIs), impurities, and intermediates. Alyssa also joined a multidisciplinary team in supporting in silico assessments of mutagenic impurities during her time in ARD. In 2019, she transferred to Drug Safety Research and Development at Pfizer where she worked in Genetic Toxicology, advancing her subject matter expertise in mutagenic impurity assessments and running the exploratory Ames assay. Most recently, in September 2022, Alyssa began her role as a Senior Scientist in Toxicology Impurity Risk Management within Drug Safety Research and Development at Pfizer. She continues to support in silico mutagenic impurity assessments in addition to contributing to the development of nitrosamine risk assessments.
DAY 1: NOVEMBER 30th, 2023
SESSION: Setting acceptable intakes (AIS) for complex nitrosamines
◆ Categorizing and deriving AIs for complex API-like nitrosamines.
◆ Two to three specific case studies providing examples of how AIs were derived based on experimental data.
